We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+150.31%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$412M
Cap. Flow
+$25.7M
Cap. Flow %
2.41%
Top 10 Hldgs %
48.66%
Holding
270
New
60
Increased
70
Reduced
50
Closed
53

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$27.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.5M
3
ROIV icon
Roivant Sciences
ROIV
+$17.4M
4
ETNB
89bio
ETNB
+$12.6M
5
JANX icon
Janux Therapeutics
JANX
+$7.04M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$105M
2
PRTA icon
Prothena Corp
PRTA
+$14.6M
3
CGON icon
CG Oncology
CGON
+$7.97M
4
SAGE
Sage Therapeutics
SAGE
+$6.58M
5
VERV
Verve Therapeutics
VERV
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.19%
2 Financials 1.65%
3 Communication Services 0.09%
4 Consumer Discretionary 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
101
BioNTech
BNTX
$23.3B
$986K 0.09%
+10,000
New +$1.07M
CTNM
102
Contineum Therapeutics
CTNM
$565M
$916K 0.09%
77,961
-88,838
-53% -$716K
AVR
103
Anteris Technologies
AVR
$845M
$889K 0.08%
197,615
-333,900
-63% -$1.31M
TECX
104
Tectonic Therapeutic
TECX
$578M
$879K 0.08%
56,007
-17,498
-24% -$361K
WVE icon
105
Wave Life Sciences
WVE
$1.18B
$872K 0.08%
119,067
+4,253
+4% +$34.4K
KVAC
106
CALL
DELISTED
Keen Vision Acquisition Corp
KVAC
$863K 0.08%
+75,000
New +$862K
PHVS icon
107
Pharvaris
PHVS
$2.42B
$851K 0.08%
34,124
– –
URGN icon
108
CALL
UroGen Pharma
URGN
$2.3B
$798K 0.08%
+40,000
New +$718K
LLY icon
109
Eli Lilly
LLY
$1.05T
$763K 0.07%
1,000
+500
+100% +$372K
LRMR icon
110
Larimar Therapeutics
LRMR
$425M
$761K 0.07%
235,689
-1,916
-0.8% -$7.18K
SRRK icon
111
Scholar Rock
SRRK
$6.24B
$748K 0.07%
20,087
-19,590
-49% -$685K
DNLI icon
112
Denali Therapeutics
DNLI
$3.87B
$748K 0.07%
51,516
+15,800
+44% +$227K
ACRS icon
113
Aclaris Therapeutics
ACRS
$814M
$710K 0.07%
+373,682
New +$651K
LITS
114
Lite Strategy Inc
LITS
$32M
$708K 0.07%
+292,397
New +$1.21M
ARVN icon
115
Arvinas
ARVN
$570M
$704K 0.07%
82,591
-46,176
-36% -$350K
URGN icon
116
UroGen Pharma
URGN
$2.3B
$698K 0.07%
35,000
+25,000
+250% +$449K
FULC icon
117
CALL
Fulcrum Therapeutics
FULC
$292M
$690K 0.06%
+75,000
New +$543K
SUPN icon
118
Supernus Pharmaceuticals
SUPN
$2.72B
$689K 0.06%
+14,418
New +$581K
DAY
119
DELISTED
Dayforce
DAY
$689K 0.06%
+10,000
New +$622K
MAZE
120
Maze Therapeutics
MAZE
$1.54B
$675K 0.06%
+26,045
New +$440K
EWTX icon
121
Edgewise Therapeutics
EWTX
$4.59B
$649K 0.06%
40,000
– –
BABA icon
122
Alibaba
BABA
$306B
$639K 0.06%
+3,578
New +$469K
GERN icon
123
Geron
GERN
$962M
$625K 0.06%
456,176
+15,000
+3% +$20K
SPRY icon
124
ARS Pharmaceuticals
SPRY
$599M
$595K 0.06%
+59,230
New +$850K
SYRE icon
125
Spyre Therapeutics
SYRE
$9.16B
$571K 0.05%
34,051
– –
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, ADAR1 Capital Management held 270 positions worth $1.06B, up 63% from $652M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

ADAR1 Capital Management's Q3 2025 filing shows 60 new, 70 increased, 50 reduced and 53 closed positions. Its largest new stake was Invivyd: 7,370,987 shares worth $8.11M. The largest sale was Abivax, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

  • ADAR1 Capital Management's largest Q3 2025 buy was Invivyd: 7,370,987 shares worth $8.11M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2025, an estimated $27.6M increase.
  • ADAR1 Capital Management's biggest Q3 2025 reduction was Abivax, cutting an estimated $105M.
  • ADAR1 Capital Management fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.58M.
  • ADAR1 Capital Management's ten largest holdings make up 49% of its $1.06B portfolio in Q3 2025.
  • ADAR1 Capital Management opened 60 new positions and closed 53 in Q3 2025.
  • ADAR1 Capital Management's portfolio value rose 63% quarter-over-quarter to $1.06B.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.